Mandate Vinge advises Xspray Pharma in connection with a directed share issue

January 31, 2018

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraordinary general meeting, whereby the company will receive approximately SEK 88 million before transaction costs.


The issue proceeds will primarily be invested in the development of new drug candidates, based on Xspray Pharma’s HyNap-platform. The share issue will be fully subscribed in accordance with separate agreements with the selected investors. Shareholders representing approximately 67.2 percent of Xspray Pharma’s shares have undertaken to vote in favor of the share issue at an extraordinary general meeting.

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. The company’s shares are admitted to trading on Nasdaq First North.

Vinge’s team consists of Dain Hård Nevonen, Sabina Börjesson, Nils Fredrik Dehlin and Ramin Baradaran.

Vinge is awarded “The Top Firm in Sweden” in WTR 1000’s latest ranking

Vinge receives the highest ranking in the World Trademark Review list of the year’s rankings. The firm obtains the Guide’s foremost ranking, which also highlights specific experts.
February 18, 2021

Insurance services in Sweden – a summary 2021

Vinge’s insurance team has written a brief summary of some of the main features of the Swedish regulations affecting foreign insurers with existing or contemplated business activities in Sweden.
February 09, 2021

Summary of employment related news in Sweden as of January 2021

Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021